The Health Impacts of Better Access to Axicabtagene Ciloleucel: The Case of Spain

In this study, the health impacts of improving access to treatment with axicabtagene ciloleucel (axi-cel) was assessed in patients with relapsed/refractory diffuse large B-cell lymphoma after ≥2 lines of therapy in Spain. A partitioned survival mixture cure model was used to estimate the lifetime ac...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-08, Vol.16 (15), p.2712
Main Authors: Córdoba, Raúl, López-Corral, Lucía, Presa, María, Martín-Escudero, Victoria, Vadgama, Sachin, Casado, Miguel Ángel, Pardo, Carlos
Format: Article
Language:English
Subjects:
B-cell lymphoma
Cancer
Care and treatment
Cell therapy
Chemotherapy
Comparative analysis
Cost analysis
Development and progression
Epidemiology
Health aspects
Lymphocytes B
Lymphocytes T
Lymphoma
Medical prognosis
Medical research
Medicine, Experimental
Mortality
Non-Hodgkin's lymphomas
Patients
Response rates
T cells
Transplants & implants
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study, the health impacts of improving access to treatment with axicabtagene ciloleucel (axi-cel) was assessed in patients with relapsed/refractory diffuse large B-cell lymphoma after ≥2 lines of therapy in Spain. A partitioned survival mixture cure model was used to estimate the lifetime accumulated life years gained (LYG) and quality-adjusted life years (QALYs) per patient treated with axi-cel versus chemotherapy. Efficacy data were extracted from the ZUMA-1 trial for axi-cel and from the SCHOLAR-1 study for chemotherapy. In the base case, the incremental outcomes of axi-cel versus chemotherapy were evaluated in a cohort of 187 patients treated with CAR T-cell therapies, as reported by the "Spanish National Health System Plan for Advanced Therapies", and in the alternative scenario in the full eligible population based on epidemiological estimates (n = 490). Taking those currently treated with axi-cel, compared with chemotherapy, axi-cel provided an additional 1341 LYGs and 1053 QALYs. However, when all eligible patients (n = 490) were treated, axi-cel provided an additional 3515 LYs and 2759 QALYs. Therefore, if all eligible patients were treated with axi-cel rather than those currently treated as per the registry (n = 187), there would have been an additional 303 patients treated, resulting in an additional 2173 LYGs and 1706 QALYs in total. The lack of access in Spain has led to a loss of a substantial number of LYGs and QALYs, and efforts should be made to improve access for all eligible patients.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16152712